Related Experiment Videos
Medication changes based on echocardiography in dialysis patients
Chun K Chong1, Michael Muzoora, George J Eckert
1Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
Insights
Serial screening echocardiography in dialysis patients did not significantly alter cardioprotective medication use. These findings suggest routine echocardiograms may not offer added benefit for optimizing cardiovascular disease management in this high-risk population.
Area of Science:
- Nephrology
- Cardiology
- Medical Imaging
Background:
- Dialysis patients face elevated cardiovascular risk.
- Kidney/Disease Outcome Quality Initiative (K/DOQI) guidelines advocate for echocardiography to detect cardiac disease.
- Current K/DOQI guidelines recommend baseline echocardiography at dialysis initiation and every 3 years thereafter.
Purpose of the Study:
- To investigate whether serial screening echocardiography influences cardioprotective medication adjustments in dialysis patients.
- To test the hypothesis that echocardiography does not alter medication regimens in this population.
Main Methods:
- Retrospective analysis of medication administration in 231 dialysis patients.
- Comparison of medication changes in patients with and without echocardiograms.
- Analysis focused on medication classes including beta blockers, ACEI/ARBs, nitrates, CCBs, and statins.
Main Results:
- Only 19% of patients in the echocardiogram group had at least one medication class change post-procedure.
- No significant difference in medication class changes was observed between the echocardiogram and no-echocardiogram groups.
- Specific medication classes showed minimal changes, with no statistically significant impact attributed to echocardiography.
Conclusions:
- The occurrence of medication changes post-echocardiography in dialysis patients is infrequent and comparable to routine care.
- Serial screening echocardiography may not provide additional benefits for optimizing cardiovascular disease management in dialysis patients.
- Further research is needed to establish the evidence for serial screening echocardiography in this high-risk group.
Abstract:
Kidney/Disease Outcome Quality Initiative (K/DOQI) guidelines recommend baseline echocardiography at the initiation of dialysis and every 3 years thereafter in patients for early detection of cardiac disease to optimize medical therapy. Because dialysis patients are at increased cardiovascular risk and thus most are already on cardioprotective medications, we hypothesize that serial screening echocardiography will not alter cardioprotective medications in dialysis patients. Retrospective analysis of medication administration of 231 dialysis patients was conducted. Patients were divided into 2 groups, those with and those without echocardiograms. Medication changes post echocardiography were compared with subjects without echocardiograms at comparable time points. The primary end point was the number of medication class changes that occurred in 2 months post echocardiography. Medication classes examined were beta blockers (BB), angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB), nitrates, calcium channel blockers (CCB), and statins. In the Echo group, there were 29 (19%) subjects with at least 1 medication class change post echocardiography, compared with 121 (81%) subjects without change. The number of patients on specific medication classes before and after echocardiography were BB (90 [60%] vs. 97 [65%], P=0.05), ACEI/ARB (74 [49%] vs. 82 [55%], P=0.01), nitrates (34 [23%] vs. 33 [22%], P=0.56), CCB (77 [51%] vs. 79 [53%], P=0.56), and statins (69 [46%] vs. 70 [47%], P=0.71). When compared with the No Echo group, there was no significant change in number of any medication classes. The occurrence of medication changes post echocardiography in dialysis patients is low and is not different than changes in routine care of dialysis patients without echocardiograms. Thus, serial screening echocardiography may not have added benefit to optimizing medical management of cardiovascular disease in dialysis patients. Further studies are warranted to demonstrate evidence for the use of serial screening echocardiography in this high-risk population.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Diuretics
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion, evaluates...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Chronic Kidney Disease IV: Nursing Management